Published in Hepatitis Weekly, January 15th, 2007
Sites in the United States and in Europe are scheduled to participate in the study and are expected to begin dosing patients in early 2007. The multicenter Phase 3 trial, known as PHAST (Phase 3 HeplisAv Short-regimen Trial), will compare a two-dose regimen of Heplisav administered at 0- and 1-month to the conventional three-dose regimen of Engerix-B. The enrollment target of the study is 1,740 subjects, ages 11 to 55 years.
"In several previous clinical studies, Heplisav has been shown to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.